Max Gelman (@MaxGelman) header
Max Gelman (@MaxGelman) profile picture

Max Gelman

@MaxGelman

Reporting on pharma and biotech, @endpts. Baseball fan, Northwestern alum. Email: [email protected]

Endpts.com
Joined May 2011
  • Tweets12.3K
  • Following482
  • Followers2.1K
430Media
Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)Photo by Max Gelman (@MaxGelman)
Neumora fail: First Phase 3 for depression drug is an unequivocal miss. The company is still running two other identical Phase 3 trials, @ky_lahucik has the latest. $NMRA -79% endpts.com/neumoras-major-de…
Neumora's major depression drug flunks first of three Phase 3 trials

Neumora's major depression drug flunks first of three Phase 3 trials

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials for its experimental major depression drug, saying Thursday that navacapr...

endpoints.news
1
2
1,346
FDA approved Vertex's "vanza triple" formulation for cystic fibrosis, and new mutations for Trikafta. Both come with boxed warnings news.vrtx.com/news-releases/…

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to...

- Approximately 300 more people with cystic fibrosis in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Dec....

news.vrtx.com
1
1
4
843
Vanza triple PR: news.vrtx.com/news-releases/…
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the...

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the...

- ALYFTREK ™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head...

news.vrtx.com
1
379
Now updated and with new version of the chart! $NVO $LLY $VKTX $RHHBY
Image from Elizabeth Cairns (@ByLizC)
Endpoints News (@endpts) profile pictureEndpoints News
@endpts20 Dec 2024
BREAKING: Novo Nordisk's CagriSema fails to hit 25% weightloss benchmark in Phase 3 readout. Novo’s stock $NVO crashed by as much as 26% pre-market Friday. endpts.com/novo-reveals-23-w…
Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Novo Nordisk's CagriSema achieves 22.7% weight loss in Phase 3 trial, missing 25% target. Stock drops 26% as results fall short of expectations.

endpoints.news
6
17
116
38,483
This will be one to watch. Sorriso says it has figured out how to make an orally-administered antibody, and is claiming success in Phase 1b study in ulcerative colitis. @MaxGelman has the details for @endpts - endpts.com/sorriso-claims-a-…
Exclusive: Can oral antibodies work? A small startup thinks it has an answer

Exclusive: Can oral antibodies work? A small startup thinks it has an answer

A private startup from Salt Lake City aiming to develop oral antibodies says it has succeeded in an early trial, a potentially significant scientific advancement in a world where systemic ...

endpoints.news
1
2
8
785
Sarepta has a long & controversial history of getting Duchenne drugs OK’d w/accelerated approval. Now it will try in more rare diseases. "We will apply that same focus and creative energy and patient-mission approach to these therapies," the CEO said. endpts.com/sarepta-arrowhead…

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of biobucks in recent years.

endpoints.news
374
The FDA has approved BridgeBio's rare heart disease drug, notably including mortality on the label. BridgeBio will brand the drug as Attruby, and it will cost about $245K per year. $BBIO endpts.com/fda-approves-brid…
FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

The FDA approved BridgeBio’s ​​acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost...

endpoints.news
19
1
58
14,299
RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try endpts.com/could-trump-and-r…
RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

As the healthcare priorities of President-elect Donald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea gaining steam is a ban on direct-to-consumer pharmaceutical advertising. Both...

endpoints.news
1
2
732
Sage reports Phase 2 failure in Huntington's disease, ends drug's development $SAGE endpts.com/sage-reports-phas…
Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development

Updated: Sage reports Phase 2 failure in Huntington's disease, ends drug's development

Sage’s final hope to turn its business around has failed, leaving the future of the once high-flying company and its postpartum depression drug uncertain.

endpoints.news
531
NEW: Me and @RLCscienceboss took a look at how Sage's upcoming Huntington's readout could be its last, best hope at turning the ship around endpts.com/a-rare-neurologic…
A rare neurological disease is Sage’s last, best hope after failures in depression

A rare neurological disease is Sage’s last, best hope after failures in depression

In 2010, neuroscientist and former Eli Lilly research leader Steve Paul started a company that he hoped would spark a revolution in drug discovery built around a class of compounds dubbed neuroster...

endpoints.news
1
204
Re-upping my piece from last week on a potential FDA commissioner under an RFK Jr.-led HHS
Max Gelman (@MaxGelman) profile pictureMax Gelman@MaxGelman6 Nov 2024
Biotech industry worries over potential for RFK Jr. ally as FDA pick endpts.com/biotech-industry-…
Biotech industry worries over potential for RFK Jr. ally as FDA pick

Biotech industry worries over potential for RFK Jr. ally as FDA pick

US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...

endpoints.news
4
9
4,047
Biotech industry worries over potential for RFK Jr. ally as FDA pick endpts.com/biotech-industry-…
Biotech industry worries over potential for RFK Jr. ally as FDA pick

Biotech industry worries over potential for RFK Jr. ally as FDA pick

US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...

endpoints.news
2
5
1
12
7,092
Max Gelman retweeted
Eric Topol (@EricTopol) profile picture
Eric Topol
@EricTopol31 Oct 2024
Two outstanding pieces by @kakape on misinformation, open-access, @ScienceMagazine science.org/content/article/… science.org/content/article/…
The five biggest challenges facing misinformation researchers

The five biggest challenges facing misinformation researchers

The burgeoning field is still grappling with fundamental problems, from getting access to data to defining 'misinformation' in the first place

science.org
6
58
7
167
50,606
Hints of impatience grow with Biogen as it tries to find a bridge to growth endpts.com/biogen-seeks-grow…
Hints of impatience grow with Biogen as it tries to find a bridge to growth

Hints of impatience grow with Biogen as it tries to find a bridge to growth

Biogen's investors are growing restless. Wednesday's third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year guidance, and sales of its...

endpoints.news
1
241
What would RFK Jr. do on healthcare? Trump ally's FDA plans raise alarm - endpts.com/what-would-rfk-jr…
Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Donald Trump's embrace of Robert F. Kennedy Jr. is forcing biotech and pharma leaders to grapple with having US life sciences policy influenced by a figure who has extensively criticized ...

endpoints.news
1
9
1
7
3,637
NEW: Eli Lilly says a slightly tweaked dosing regimen of its Alzheimer's drug Kisunla can lower the rate of brain swelling side effects endpts.com/in-bid-to-lower-a…
In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer's drug

In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer's drug

Eli Lilly presented new data illustrating how a different dosing regimen of its Alzheimer’s drug reduced the frequency of brain swelling. The results could help Lilly argue for a change ...

endpoints.news
1
1
243
Evergreen reminder to always double check who you’re emailing before hitting send Ex-Pfizer CFO emailed CEO Albert Bourla over the weekend. The message was blank. But the “to” field included a rep for activist Starboard From @ArmstrongDrew @maxonwifi endpts.com/behind-the-scenes…
Exclusive: How an accidental email tipped Pfizer off to an activist investor’s plan

Exclusive: How an accidental email tipped Pfizer off to an activist investor’s plan

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from his former CFO Frank D’Amelio. While there was no ...

endpoints.news
1
15
1
42
19,959
This year’s Women in Biopharma R&D report is dedicated to Natalie Grover, who launched the project with @AmberTongPW in 2019 while they were working at Endpoints. We’re proud to continue their tradition of honoring 20 exceptional women leaders. endpts.com/special-report-20…
Special report 2024: Meet 20 women breaking new ground in biopharma R&D

Special report 2024: Meet 20 women breaking new ground in biopharma R&D

Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie passed away earlier ...

endpoints.news
1
9
1
12
3,215
FDA approves first new schizophrenia drug in decades --> drug was centerpiece of Bristol Myers Squibb's $14B buyout of Karuna $BMY endpts.com/fda-approves-bris…
FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

The FDA on Thursday approved Bristol Myers Squibb’s new schizophrenia drug in one of the year’s most anticipated regulatory decisions. The approval gives Bristol Myers a significant foothold in the...

endpoints.news
1
1
303
The Federal Reserve cut interest rates by 50 bps. What does that mean for biotech, pharma and venture capital? endpts.com/what-does-todays-…
Here's what today's Fed rate cut means for biotech, pharma and venture capital

Here's what today's Fed rate cut means for biotech, pharma and venture capital

The Federal Reserve made its long-anticipated interest rate cuts on Wednesday, lowering rates by a half of a percentage point. It's the first time the Fed has cut interest rates ...

endpoints.news
2
6
412
Load more